Skip to main content
    M

    Madrigal Pharmaceuticals Inc (MDGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $421.99
    -1.97 (-0.46%)

    Market Cap: $9.93B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Madrigal Pharmaceuticals Inc (MDGL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Madrigal Pharmaceuticals (MDGL) has a market cap of $9.93B and an enterprise value of $9.75B. Revenue grew 92.80% over the last 12 months from the 12 months before. It kept -10.89% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 1.75% below the market cap, as cash exceeds debt.

    Market Cap$9.93B
    Enterprise Value$9.75B
    Latest price (Nov 17, 2026)$421.99

    Key Dates

    The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 17, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.35% in the quarter ended Sep 30, 2026 and grew 15.97% a year over 2 years.

    Shares Outstanding29.25M
    Shares Change (YoY)+2.59%
    Shares Change (QoQ)+0.35%
    Share Count Growth (2Y CAGR)+15.97%

    Valuation Ratios

    Sales and book value multiples are 8.6x and 19.7x.

    P/S Ratio8.6x
    Forward P/S6.3x
    P/B Ratio19.7x
    P/TBV Ratio19.9x

    Price Statistics

    The stock is down 20.26% over 52 weeks and trades 10.43% below its 50-day average.

    Beta (1Y)0.44
    52-Week Change-20.26%
    1-Month Change-5.61%
    3-Month Change-21.88%
    6-Month Change-17.55%
    5-Year Change+453.52%
    10-Year Change+2508.24%
    Total Return (1Y)-20.26%
    Total Return (3Y CAGR)+33.67%
    Total Return (5Y CAGR)+38.35%
    Return vs SPY (1Y)-36.07%
    Max Drawdown (1Y)-34.26%
    Max Drawdown (3Y)-34.26%
    Sharpe Ratio (1Y)-0.67
    Correlation with SPY (1Y)0.14
    50-Day Average$471.14
    200-Day Average$495.33
    52-Week Range$353.54 to $615.00
    RSI (14 Days)40.1
    Average Volume (20 Days)592.06K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.05x current liabilities, and total debt is 0.54x shareholder equity.

    Current Ratio3.05x
    Quick Ratio2.78x
    Debt / Equity0.54x
    Interest Coverage-4.86x

    Returns and Efficiency

    Return on invested capital is -12.75% over the last 12 months, against a 5-year average of -25.19%.

    Return on Equity (ROE)-24.80%
    Return on Assets (ROA)-10.84%
    Return on Invested Capital (ROIC)-12.75%
    ROE (5Y Average)-94.94%
    ROA (5Y Average)-59.17%
    ROIC (5Y Average)-25.19%
    Asset Turnover1.02x
    Receivables Turnover6.80x

    Scores

    MDGL has an Altman Z-Score of 8.45, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score8.45
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $1.43B over the last 12 months.

    Revenue$1.43B
    Revenue Growth (YoY)+92.80%
    Gross Profit$1.43B
    Operating Income-$152.65M
    Pretax Income-$155.46M
    Net Income-$155.46M
    EBITDA-$149.38M
    Reported EPS (TTM)-$4.11

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 43.84% of the $1.43B in total assets.

    Cash and Equivalents$514.64M
    Total Debt$341.27M
    Net Cash$173.37M
    Net Cash Per Share$5.93
    Working Capital$932.87M
    Shareholder Equity$626.94M
    Book Value Per Share$21.44
    Tangible Book Value$619.85M
    Tangible Book Per Share$21.19
    Total Assets$1.43B
    Total Liabilities$807.45M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $12.42M of capital spending, operating cash flow left -$169.43M of free cash flow.

    Operating Cash Flow-$157.01M
    Capital Expenditures$12.42M
    Free Cash Flow-$169.43M
    FCF Per Share-$7.33
    Depreciation and Amortization$6.87M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -10.69%.

    Gross Margin100.00%
    Operating Margin-10.69%
    Pretax Margin-10.89%
    Net Margin-10.89%
    EBITDA Margin-10.46%
    FCF Margin-11.87%

    Growth

    Book Value Per Share Growth (2Y CAGR)+14.44%
    Tangible Book Per Share Growth (2Y CAGR)+13.74%

    Revenue and profit by year

    Dividends and Yields

    MDGL does not pay a dividend. Its free cash flow yield is -1.37%.

    FCF Yield-1.37%
    Buyback Yield-0.08%
    Shareholder Yield-0.08%

    Stock Splits

    The last split was a 1-for-35 reverse split on Jul 25, 2016.

    Last Split DateJul 25, 2016
    Split TypeReverse split
    Split Ratio1:35

    Peer Position

    Against 8 similar companies, MDGL has the lowest P/S.

    P/S Ratio8.6x vs 17.3x median
    ROIC-12.75% vs -36.51% median
    Revenue Growth (Trailing 4 Quarters, YoY)+92.80% vs +51.61% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 51.01% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+51.01%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About MDGL

    What is MDGL's market cap?

    Madrigal Pharmaceuticals has a market cap of $9.93B. Its enterprise value, which adds debt and subtracts cash, is $9.75B.

    How many shares of MDGL are outstanding?

    Madrigal Pharmaceuticals has 29.25M shares outstanding. The count is up 2.59% from a year earlier.

    Does MDGL pay a dividend?

    No. Madrigal Pharmaceuticals does not pay a dividend.

    How much debt does MDGL have?

    Madrigal Pharmaceuticals has $341.27M of total debt and $514.64M of cash and equivalents, a net cash position of $173.37M.